EP 2648736 A2 20131016 - CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
Title (en)
CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
Title (de)
CYCLOALKYL-GUANIDIN-F1F0-ATPASE-HEMMER UND THERAPEUTISCHE VERWENDUNGEN DAVON
Title (fr)
COMPOSÉS CYCLOALKYLGUANIDINES INHIBITEURS DE LA F1F0-ATPASE ET LEURS UTILISATIONS
Publication
Application
Priority
- US 42089910 P 20101208
- US 2011063943 W 20111208
Abstract (en)
[origin: WO2012078867A2] The invention provides cycloalkyl guanidine compounds that inhibit F1F0-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.
IPC 8 full level
A61K 31/55 (2006.01); A61K 31/45 (2006.01); C07D 213/74 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 241/24 (2006.01); C07D 295/185 (2006.01)
CPC (source: EP)
C07C 279/22 (2013.01); C07C 311/07 (2013.01); C07C 317/44 (2013.01); C07D 213/74 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 239/42 (2013.01); C07D 241/24 (2013.01); C07D 261/14 (2013.01); C07D 277/56 (2013.01); C07D 295/185 (2013.01); C07D 333/38 (2013.01); C07C 2601/02 (2017.04); C07C 2601/04 (2017.04); C07C 2601/08 (2017.04); C07C 2601/14 (2017.04)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2012078867 A2 20120614; WO 2012078867 A3 20140403; AU 2011338302 A1 20130711; CA 2820035 A1 20120614; EP 2648736 A2 20131016; EP 2648736 A4 20150429
DOCDB simple family (application)
US 2011063943 W 20111208; AU 2011338302 A 20111208; CA 2820035 A 20111208; EP 11846884 A 20111208